DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Pembrolizumab is an investigational drug.
There have been 863 clinical trials for Pembrolizumab. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are seventy-four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Pembrolizumab
|Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer||University Hospital, Geneva||Phase 2|
|TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer||Merck Sharp & Dohme Corp.||Phase 2|
|TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast Cancer||The Methodist Hospital System||Phase 2|
Top disease conditions for Pembrolizumab
Top clinical trial sponsors for Pembrolizumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pembrolizumab||Start Trial||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|Pembrolizumab||Start Trial||Antibody-drug conjugates and immunotoxins||Oncomatryx Biopharma, S.L. (Derio, ES)||Start Trial|
|Pembrolizumab||Start Trial||Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof||KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)||Start Trial|
|Pembrolizumab||Start Trial||Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy||MedImmune Limited (Cambridge, GB)||Start Trial|
|Pembrolizumab||Start Trial||Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts||Advenchen Pharmaceuticals, LLC (Moorpark, CA)||Start Trial|
|Pembrolizumab||Start Trial||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pembrolizumab||European Patent Office||3313818||2035-06-26||Start Trial|
|Pembrolizumab||World Intellectual Property Organization (WIPO)||2016210262||2035-06-26||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|